2'(β)-Hydroxymethylated adenosine is a potent and selective inhibitor of hepatitis C virus (HCV) replication. It targets the RNA-dependent RNA polymerase of HCV, NS5B. Synthesis and antiviral evaluation of carbocyclic versions are described. The cyclopentene intermediate (9β) was successfully synthesized through sequential Johnson-Claisen orthoester rearrangement and ring-closing metathesis (RCM). Coupling of bases via a Pd(0) catalyst, selective dihydroxylation, and desilylation yielded the target nucleoside analogues. The compounds 17 and 18 were assayed for their ability to inhibit HCV RNA replication in a subgenomic replicon Huh7 cell line and showed moderate antiviral activity with toxicity up to 20.0 and 24.7 µg/mL, respectively.
Introduction

Hepatitis C virus (HCV)
1-3 is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Current therapy based on pegylated interferon and ribavirin is often poorly tolerated and effective in only 50% of patients. More effective therapeutic agents against HCV are needed.
Nucleoside analogues are the drugs of choice in the treatment of viral infection, and were synthesized and evaluated for anti-HCV activity. [4] [5] [6] These nucleosides are incorporated into proviral RNA and act as chain terminators. 7 Modification around the 2'-hydroxy group of the ribose in natural ribonucleosides can produce effective RNA chain termination. 8 For example, 2'-C-methylcytidine (1) 9 and 2'-C-methyladenosine (2) 10 are potent anti-HCV agents in clinical trials.
In 2006, Yoo et al. reported the synthetic procedure and potent anti-HCV activity of 2'-C-hydroxymethyladenosine (3). 11 Based on these findings, we designed and synthesized novel carbocyclic classes of nucleosides comprising 2'-C-hydroxymethylated carbodine analogues (Fig. 1 ).
Results and Discussion
Chemistry. The γ,δ-unsaturated ethyl ester 5 was readily synthesized from the commercially available 2-butene-1,4-diol (4) using the reported procedure. 12 The ester 5 was reduced to the corresponding aldehyde 6 using DIBAL-H in toluene at -78 o C. The condensation of 6 with the lithium reagent prepared from 3 equivalents of 2-bromo-allyloxy-tert-butyldimethylsilane 7 and 2.5 equivalents of butyllithium in THF at -110 o C yielded diene analogue 8 13 (Scheme 1). The diene analogue 8 diastereomeric mixture was subjected to ring-closing metathesis (RCM) conditions [14] [15] [16] [17] [18] to yield cyclo- 2'-C-Me-C: 2'-C-Methylcytidine. EC50 (µg/mL): concentration required to inhibit 50% of the virus induced cytopathicity. CC50 (µg/mL): concentration required to reduce cell viability by 50%.
pentenol derivatives 9α and 9β. The stereochemical differences between the two isomers were determined by NOE comparisons. Irradiation of C1-H, produced different NOE patterns at the proximal hydrogens of compound 9β [methyloxy-H (0.19%)] compared to compound 9α [methyloxy-H (0.08%)] (Fig. 2) .
Compound 9β was converted into 10 using ethyl chloroformate, and readily coupled with cytosine and adenine by allylic functionalization using a palladium catalyst adduct to generate nucleoside analogues 11 and 12, respectively. Carbodine analogues were obtained by oxidation of the protected nucleosides 11 and 12 to yield dihydroxylated 13 and 14 as major reaction products with a small amount of 15 and 16, respectively. Stereochemical differences were determined by NOE experiments. Irradiation of C 1 -H of compound 15 produced different NOE patterns at the proximal hydrogens such as 2'-methyloxy-H (0.10%) and 3'-H (0.05%), compared with compound 13 2'-methyloxy-H (0.09%) and 3'-hydroxyl-H (0.06%) (Fig. 3) . Bulky groups such as silylated hydroxymethyl group and nucleosidic bases (adenine and cytosine) reinforce the steric hindrance of the β-faces. 19, 20 Removal of the protecting silyl group of 13 and 14 was performed by treatment with tetrabutylammonium fluoride (TBAF) to yield target nucleosides 17 and 18, respectively (Scheme 2). Antiviral Activity. The newly synthesized nucleoside analogues were assayed for anti-HCV activity using an in vitro assay system that is suitable for monitoring anti-HCV activities of compounds. This system is composed of a human hepatocarcinoma cell line (Huh-7) supporting multiplication of a HCV replication, and the results are summarized in Table 1 . These cells contain a HCV subgenomic replicon RNA encoding a luciferase reporter gene as a marker. The antiviral potency of the nucleoside analogues against the HCV replicon is expressed as EC50, which was quantified by a luciferase assay after a two-days incubation period with the tested compound. To confirm the anti-HCV potency of compounds, subgenomic replicon RNA levels were quantified by real-time RT-PCR analysis. In addition, the associated cytotoxicity (expressed as CC50 in Table 1 ) was evaluated in a tetrazolium (XTT)-based assay. 2'-C-Methylcytidine (1) was selected as the reference standard due to its structure similarity to the newly synthesized compounds. Both compounds 17 and 18 inhibited the replication of the replicon in Huh-7 cells by 50% at concentrations of 11.7 µg/mL and 18.2 µg/mL, respectively.
In summary, on the basis of potent anti-HCV activity of 2'-C-hydroxymethyladenosine, we have accomplished the stereoselective synthesis of its carbodine derivatives starting from 2-butene-1,4-diol. Compounds 17 and 18 exhibited good anti-HCV activity, indicating that the hydroxymethyl group at 2'-position of carbodine system makes the conformation to be favorable for interaction with HCV polymerase.
Experimental Section
Melting points (mp) were measured on a Mel-temp II laboratory device and are uncorrected. NMR spectra were recorded using a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan). UV spectra were obtained using a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). The elemental microanalyses were performed using a Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA).
( 
±)-3-(tert-Butyldimethylsilanyloxymethyl)-pent-4-enal
rel-(1R,4S)-1-Ethoxycarbonyloxy-2,4-bis-(tert-butyldimethylsilyloxymethyl)cyclopent-2-ene (10).
To a solution of compound 9β (1.77 g, 4.68 mmol) in anhydrous pyridine (15 mL), ethyl chloroformate (547 mg, 5.04 mmol) and DMAP (49 mg, 0.4 mmol) were added. The reaction mixture was stirred overnight at 60 o C. The reaction mixture was then quenched using a saturated NaHCO3 solution (0.5 mL) and evaporated under reduced pressure. The residue was partitioned between water and ethyl acetate and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layer extracts were washed with brine, dried over MgSO4 and filtered. The organic solvent was evaporated under reduced pressure and the residue was purified by column chromatography (silica gel, ethyl acetate-hexanes 1:25 v/v) to yield compound 10 (1.66 g, 80%) as a colorless syrup. 
